BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36401766)

  • 1. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.
    Zhang XX; Ma HB; Li TH; Huang B; Jia NY; Meng Y
    Clin Transl Oncol; 2023 Mar; 25(3):731-738. PubMed ID: 36401766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
    BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma.
    Wu TC; Deng J; Chu FI; Sadeghi S; Finn R; Agopian VG; Lee P; Raldow AC
    HPB (Oxford); 2024 Mar; 26(3):444-450. PubMed ID: 38142182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
    Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma.
    Shen ZT; Zhou H; Li AM; Li B; Shen JS; Zhu XX
    Oncotarget; 2017 Nov; 8(55):93541-93550. PubMed ID: 29212171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients.
    Chen YX; Zeng ZC; Tang ZY; Fan J; Zhou J; Jiang W; Zeng MS; Tan YS
    BMC Cancer; 2010 Sep; 10():492. PubMed ID: 20840777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.
    Barney BM; Olivier KR; Miller RC; Haddock MG
    Radiat Oncol; 2012 May; 7():67. PubMed ID: 22553982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
    Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
    JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
    Saxena A; Bester L; Chua TC; Chu FC; Morris DL
    Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
    Kopek N; Holt MI; Hansen AT; Høyer M
    Radiother Oncol; 2010 Jan; 94(1):47-52. PubMed ID: 19963295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort.
    Gupta AN; Gordon AC; Gabr A; Kalyan A; Kircher SM; Mahalingam D; Mulcahy MF; Merkow RP; Yang AD; Bentrem DJ; Caicedo-Ramirez JC; Riaz A; Thornburg B; Desai K; Sato KT; Hohlastos ES; Kulik L; Benson AB; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2022 Aug; 45(8):1117-1128. PubMed ID: 35732931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.
    Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
    Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
    J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Edeline J; Touchefeu Y; Guiu B; Farge O; Tougeron D; Baumgaertner I; Ayav A; Campillo-Gimenez B; Beuzit L; Pracht M; Lièvre A; Le Sourd S; Boudjema K; Rolland Y; Boucher E; Garin E
    JAMA Oncol; 2020 Jan; 6(1):51-59. PubMed ID: 31670746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma.
    Liu MY; Lo CH; Lin CS; Chao HL; Yang JF; Lin KT; Fan CY; Su YF; Huang WY
    Tumori; 2017 May; 103(3):236-241. PubMed ID: 28058710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.